

USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.  
An answer set can be processed to create terms only  
in the same file in which it was created.

```
=> file registry
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          0.85      12.92
```

FILE 'REGISTRY' ENTERED AT 16:33:02 ON 28 APR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5  
DICTIONARY FILE UPDATES: 27 APR 2006 HIGHEST RN 882066-77-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> sel L2
E1 THROUGH E5 ASSIGNED
```

```
=> file medline caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          0.77      13.69
```

FILE 'MEDLINE' ENTERED AT 16:33:08 ON 28 APR 2006

FILE 'CAPLUS' ENTERED AT 16:33:08 ON 28 APR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> s E1-E5
L3      2036 ("(±)-E 2020"/BI OR DONEPEZIL/BI OR "1-BENZYL-4-((5,6-DIMETHO
        XY-1-OXOINDAN-2-YL)METHYL) PIPERIDINE"/BI OR 120014-06-4/BI OR
        142057-79-2/BI)
```

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s donepezil

L1 5 DONEPEZIL

=> s donepezil/cn

L2 1 DONEPEZIL/CN

=> d L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 120014-06-4 REGISTRY

ED Entered STN: 07 Apr 1989

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN ( $\pm$ )-E 2020

CN 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine

CN Donepezil

FS 3D CONCORD

DR 142057-79-2

MF C24 H29 N O3


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

578 REFERENCES IN FILE CA (1907 TO DATE)

14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

580 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.86

12.07

FILE 'MEDLINE' ENTERED AT 16:32:46 ON 28 APR 2006

FILE 'CAPLUS' ENTERED AT 16:32:46 ON 28 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> sel L2

NO ANSWERS SELECTED. THE ANSWER SET WAS CREATED IN FILE 'REGISTRY'.

```
=> s L3 and py<2003
1 FILES SEARCHED...
L4          970 L3 AND PY<2003
```

```
=> sL4 and (MMSE or (mini Mental State Exam))
SL4 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s L4 and (MMSE or (mini Mental State Exam))
L5          55 L4 AND (MMSE OR (MINI MENTAL STATE EXAM))
```

```
=> dup rem L5
PROCESSING COMPLETED FOR L5
L6          39 DUP REM L5 (16 DUPLICATES REMOVED)
```

```
=> d L6 1-39 ti
```

```
L6  ANSWER 1 OF 39      MEDLINE on STN                DUPLICATE 1
TI  Effects of long-term Donepezil therapy on rCBF of Alzheimer's
    patients.

L6  ANSWER 2 OF 39      MEDLINE on STN                DUPLICATE 2
TI  Brain perfusion follow-up in Alzheimer's patients during treatment with
    acetylcholinesterase inhibitors.

L6  ANSWER 3 OF 39      MEDLINE on STN                DUPLICATE 3
TI  Donepezil and rivastigmine in the treatment of Alzheimer's
    disease: a best-evidence synthesis of the published data on their efficacy
    and cost-effectiveness.

L6  ANSWER 4 OF 39      MEDLINE on STN
TI  Donepezil for cognitive impairment in Parkinson's disease: a
    randomised controlled study.

L6  ANSWER 5 OF 39      MEDLINE on STN                DUPLICATE 4
TI  Donepezil treatment of vascular dementia.

L6  ANSWER 6 OF 39      MEDLINE on STN
TI  The efficacy of donepezil in Alzheimer's disease.

L6  ANSWER 7 OF 39      MEDLINE on STN
TI  Donepezil in the treatment of Alzheimer's disease: long-term
    efficacy and safety.

L6  ANSWER 8 OF 39      MEDLINE on STN                DUPLICATE 5
TI  Donepezil for the treatment of behavioral symptoms in patients
    with Alzheimer's disease.

L6  ANSWER 9 OF 39      CAPLUS  COPYRIGHT 2006 ACS on STN
TI  The preservation of function in Alzheimer's disease: Results from a
    1-year, placebo-controlled study with donepezil

L6  ANSWER 10 OF 39     MEDLINE on STN
TI  Successful treatment of behavioural problems in dementia using a
    cholinesterase inhibitor: the ethical questions.

L6  ANSWER 11 OF 39     MEDLINE on STN
TI  Comparison of functional and cognitive donepezil effects in
    Alzheimer's disease.

L6  ANSWER 12 OF 39     MEDLINE on STN                DUPLICATE 6
TI  Treatment with donepezil in Alzheimer patients with and without
```

cerebrovascular disease.

- L6 ANSWER 13 OF 39 MEDLINE on STN  
TI Measuring cognition in advanced Alzheimer's disease for clinical trials.
- L6 ANSWER 14 OF 39 MEDLINE on STN DUPLICATE 7  
TI Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy.
- L6 ANSWER 15 OF 39 MEDLINE on STN DUPLICATE 8  
TI Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease.
- L6 ANSWER 16 OF 39 MEDLINE on STN  
TI A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
- L6 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: Cholinesterase inhibitors versus nootropics
- L6 ANSWER 18 OF 39 MEDLINE on STN DUPLICATE 9  
TI The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia.
- L6 ANSWER 19 OF 39 MEDLINE on STN  
TI Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.
- L6 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Donepezil in the treatment of Alzheimer's disease Long-term efficacy and safety
- L6 ANSWER 21 OF 39 MEDLINE on STN DUPLICATE 10  
TI Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
- L6 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Ventricular measurements in computed tomography of responders and non-responders to donepezil in the treatment of Alzheimer's disease
- L6 ANSWER 23 OF 39 MEDLINE on STN DUPLICATE 11  
TI An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients.
- L6 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2006 ACS on STN  
TI Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents
- L6 ANSWER 25 OF 39 MEDLINE on STN  
TI Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
- L6 ANSWER 26 OF 39 MEDLINE on STN DUPLICATE 12  
TI Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: a retrospective, longitudinal study.
- L6 ANSWER 27 OF 39 MEDLINE on STN DUPLICATE 13  
TI Maintaining cognitive function in Alzheimer disease: how effective are current treatments?.
- L6 ANSWER 28 OF 39 MEDLINE on STN  
TI Donepezil for mild and moderate Alzheimer's disease.

L6 ANSWER 29 OF 39 MEDLINE on STN  
 TI Better cognitive and psychopathologic response to **donepezil** in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study.

L6 ANSWER 30 OF 39 MEDLINE on STN  
 TI **Donepezil** in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

L6 ANSWER 31 OF 39 MEDLINE on STN DUPLICATE 14  
 TI Effects of **donepezil** on emotional/behavioral symptoms in Alzheimer's disease patients.

L6 ANSWER 32 OF 39 MEDLINE on STN  
 TI **Donepezil** for behavioural disorders associated with Lewy bodies: a case series.

L6 ANSWER 33 OF 39 MEDLINE on STN  
 TI Sustained cognitive improvement following treatment of Alzheimer's disease with **donepezil**.

L6 ANSWER 34 OF 39 MEDLINE on STN  
 TI Economic evaluation of **donepezil** for the treatment of Alzheimer's disease in Canada.

L6 ANSWER 35 OF 39 MEDLINE on STN  
 TI [Trials and perspectives in pharmacotherapy of Alzheimer's disease]. Proby i perspektywy farmakoterapii w chorobie Alzheimer'a.

L6 ANSWER 36 OF 39 MEDLINE on STN  
 TI An economic perspective on Alzheimer's disease.

L6 ANSWER 37 OF 39 MEDLINE on STN DUPLICATE 15  
 TI A 24-week, double-blind, placebo-controlled trial of **donepezil** in patients with Alzheimer's disease. **Donepezil** Study Group.

L6 ANSWER 38 OF 39 MEDLINE on STN DUPLICATE 16  
 TI Perspectives in the management of Alzheimer's disease: clinical profile of **donepezil**.

L6 ANSWER 39 OF 39 MEDLINE on STN  
 TI The efficacy and safety of **donepezil** in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The **Donepezil** Study Group.

=> s L6 and (Severe or advanced) (W)Alzheimer's  
 MISMATCHED QUOTE 'ALZHEIMER'S'  
 Quotation marks (or apostrophes) must be used in pairs,  
 one before and one after the expression you are setting  
 off or masking.

=> s L6 and (Severe or advanced) (W)Alzheime?  
 L7 3 L6 AND (SEVERE OR ADVANCED) (W) ALZHEIME?

=> d L7 1-3 ti abs bib

L7 ANSWER 1 OF 3 MEDLINE on STN  
 TI Measuring cognition in **advanced Alzheimer's** disease for clinical trials.  
 AB Measurement of cognitive dysfunction and treatment response in the early stages of Alzheimer's disease (AD) has used such scales as the Mini-Mental State Examination (**MMSE**) and the AD Assessment Scale (ADAS).

With the exception of clinical rating scales, however, there are only a few objective measures of cognition for tracking progression in advanced AD. Given renewed interest in potential therapies for advanced AD, objective measures of cognition are important for the adequate evaluation of change due to AD progression or therapy. Several cognitive measures for advanced AD are reviewed. One measure, the Severe Impairment Battery (SIB) is reviewed in detail. Preliminary analyses from a trial of memantine show significant change on the SIB in memory ( $p < 0.001$ ) and visuospatial functions ( $p < 0.02$ ) over six-months with a trend for language and praxis. Data from a donepezil trial also highlight the importance of accurate assessment in advanced AD.

AN 2002694282 MEDLINE  
 DN PubMed ID: 12456059  
 TI Measuring cognition in advanced Alzheimer's disease  
 for clinical trials.  
 AU Schmitt F A; Cragar D; Ashford J W; Reisberg B; Ferris S; Mobius H J;  
 Stoffler A  
 CS Sanders-Brown Center on Aging, Department of Psychiatry, University of  
 Kentucky Medical Center, Lexington, KY 40536-0230, USA.  
 SO Journal of neural transmission. Supplementum, (2002) No. 62, pp.  
 135-48. Ref: 51  
 Journal code: 0425126. ISSN: 0303-6995.  
 CY Austria  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 200301  
 ED Entered STN: 14 Dec 2002  
 Last Updated on STN: 11 Jan 2003  
 Entered Medline: 10 Jan 2003

L7 ANSWER 2 OF 3 MEDLINE on STN  
 TI Efficacy of acetylcholinesterase inhibitors versus nootropics in  
 Alzheimer's disease: a retrospective, longitudinal study.  
 AB The aim of this study was to investigate the efficacy of nootropics  
 (piracetam, aniracetam, nimodopine and dihydroergocristine) versus  
 acetylcholinesterase inhibitors (AChE-Is) (tacrine and donepezil  
 ) in the treatment of Alzheimer's disease. This is a retrospective study  
 of 510 patients with Alzheimer's disease. To determine clinical efficacy  
 of treatment, we used the mean change over time in scores for the  
 following tests: the Mini-Mental State Examination (MMSE); the  
 Cambridge Cognitive Examination for the Elderly; and the Functional Rating  
 Scale for Symptoms of Dementia. In all patients and in patients with  
 severe Alzheimer's disease (baseline MMSE <  
 11), no significant differences were seen in the neuropsychological test  
 scores between the two treatment groups. In patients with moderate  
 dementia (baseline MMSE between 11 and 20), however, there was a  
 significantly greater deterioration, as shown on the CAMCOG scale, after  
 12 months' treatment for patients receiving AChE-Is compared with those  
 receiving nootropics (-4.38 for AChE-Is group versus 1.48 for nootropics  
 group). For patients with mild dementia (baseline MMSE score  
 between 21 and 26), there was a significantly greater deterioration on the  
 MMSE scale for each time-point in the nootropics group compared  
 with the AChE-Is group. In conclusion, we did not find any strong  
 evidence that a difference in efficacy exists between AChE-Is and  
 nootropics in the treatment of Alzheimer's disease.

AN 2001185760 MEDLINE  
 DN PubMed ID: 11277345  
 TI Efficacy of acetylcholinesterase inhibitors versus nootropics in  
 Alzheimer's disease: a retrospective, longitudinal study.  
 AU Tsolaki M; Pantazi T; Kazis A  
 CS Third Department of Neurology, Aristotle University of Thessaloniki,  
 Greece.. tsolakim@med.auth.gr  
 SO The Journal of international medical research, (2001 Jan-Feb)

Vol. 29, No. 1, pp. 28-36.  
 Journal code: 0346411. ISSN: 0300-0605.

CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200107  
 ED Entered STN: 23 Jul 2001  
 Last Updated on STN: 23 Jul 2001  
 Entered Medline: 19 Jul 2001

L7 ANSWER 3 OF 3 MEDLINE on STN  
 TI The efficacy and safety of **donepezil** in patients with  
 Alzheimer's disease: results of a US Multicentre, Randomized,  
 Double-Blind, Placebo-Controlled Trial. The **Donepezil** Study  
 Group.

AB This study evaluated the efficacy and safety of **donepezil** in  
 patients with mild to moderately **severe** Alzheimer's  
 disease, and examined the relationships between plasma **donepezil**  
 concentration, red blood cell acetylcholinesterase (AChE) activity and  
 clinical response. The trial was of a multicenter, double-blind,  
 parallel-group design and patients were randomised to once-daily treatment  
 with either **donepezil** (1, 3 or 5 mg) or placebo. The 12-week  
 double-blind phase was followed by a 2-week single-blind placebo washout.  
 161 patients (55-85 years of age) entered the study and 141 completed  
 treatment. Patients treated with **donepezil** showed dose-related  
 improvements in the Alzheimer's Disease Assessment Scale-cognitive  
 subscale score (ADAS-cog) and in MMSF scores. The improvements in  
 ADAS-cog were statistically significantly greater with **donepezil**  
 5 mg/day than with placebo. There was a 50% reduction in the percentage  
 of patients showing clinical decline with **donepezil** at 5 mg/day  
 (11%) relative to placebo (20%). In addition, a statistically significant  
 correlation between plasma concentrations of **donepezil** and AChE  
 inhibition was demonstrated. A plateau of inhibition (76-84%) was reached  
 at plasma **donepezil** concentrations > 50 ng/ml. The correlation  
 between plasma drug concentrations and ADAS-cog (p = 0.014), **MMSE**  
 (p = 0.023) and patient quality of life scores, assessed by the patient (p  
 = 0.037) were also statistically significant, as was the correlation  
 between AChE inhibition and change in ADAS-cog (p = 0.008). The incidence  
 of treatment-emergent adverse events with all three dosages of  
**donepezil** (64-68%) was comparable to that observed with placebo  
 (65%). **Donepezil** had no clinically significant effect on vital  
 signs, haematology or clinical biochemistry tests. Importantly,  
**donepezil** was not associated with any hepatotoxicity, as observed  
 with acridine-based cholinesterase inhibitors.

AN 97072226 MEDLINE  
 DN PubMed ID: 8915035  
 TI The efficacy and safety of **donepezil** in patients with  
 Alzheimer's disease: results of a US Multicentre, Randomized,  
 Double-Blind, Placebo-Controlled Trial. The **Donepezil** Study  
 Group.

AU Rogers S L; Friedhoff L T  
 CS Department of Clinical Research, Eisai America Inc., Teaneck, N.J.  
 07666-6741, USA.

SO Dementia (Basel, Switzerland), (1996 Nov-Dec) Vol. 7, No. 6, pp.  
 293-303.  
 Journal code: 9010348. ISSN: 1013-7424.

CY Switzerland  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (MULTICENTER STUDY)  
 (RANDOMIZED CONTROLLED TRIAL)

LA English  
 FS Priority Journals  
 EM 199702

ED Entered STN: 5 Mar 1997  
Last Updated on STN: 6 Feb 1998  
Entered Medline: 18 Feb 1997

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

55.49

69.18

STN INTERNATIONAL LOGOFF AT 16:36:50 ON 28 APR 2006